Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 12Venous Thrombosis 9Pulmonary Embolism 9Neoplasms 8Thrombosis 4Pancreatic Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Thromboembolism 2Neoplasm Metastasis 2Lymphoma 2Hemorrhage 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Thrombophilia 1Thrombocytopenia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Ovarian Neoplasms 1Obesity 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1

Interventions

apixaban 1Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mesenteric Ischemia × Dalteparin × Clear all
NCT02585713 2020-08-04

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Academic and Community Cancer Research United

Phase 3 Completed
300 enrolled 11 charts
Classical hematology

Neoplasm Metastasis, Neoplasms, Pulmonary Embolism, Venous Thrombosis, Intracranial Thrombosis, Venous Thromboembolism, Mesenteric Ischemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡